Regulation of the TUG1/miR‑145‑5p/SOX2 axis on the migratory and invasive capabilities of melanoma cells

Deng,Jiabin; Li,Yinqiu; Song,Jiaqian; Zhu,Fei

doi:10.3892/etm.2022.11535

Regulation of the TUG1/miR‑145‑5p/SOX2 axis on the migratory and invasive capabilities of melanoma cells

Authors:
- Jiabin Deng
- Yinqiu Li
- Jiaqian Song
- Fei Zhu
View Affiliations

Affiliations: Department of Burn and Plastic Surgery, The Third People's Hospital of Bengbu, Bengbu, Anhui 233000, P.R. China, Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: July 28, 2022 https://doi.org/10.3892/etm.2022.11535
Article Number: 599
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is the most prevalent malignancy of cutaneous carcinomas. Taurine‑upregulated gene 1 (TUG1), a lncRNA, is a pivotal regulator of cutaneous malignancies. The present study aimed to investigate the impact and possible mechanisms of action of TUG1 behind the progression of melanomas. Reverse transcription‑quantitative PCR was conducted to detect the expression levels of TUG1, microRNA (miR)‑145‑5p and SOX2 in melanoma tissues and cell lines. Cell Counting Kit‑8 (CCK‑8) assays were performed to measure the proliferative ability of melanoma cells and transwell assays were used to examine the migration and invasion of melanoma cells. Dual luciferase reporter and RNA immunoprecipitation (RIP) assays were utilized to identify the interactions among TUG1, miR‑145‑5p and SOX2. Western blotting and immunohistochemical assays were performed to determine the expression profile of SOX2. The impact of TUG1 on melanoma tumorigenesis was assessed using tumorigenicity assays. TUG1 expression levels were elevated in melanoma tumor tissues and cell lines. Reduced TUG1 expression levels significantly inhibited the proliferative, migratory and invasive abilities of melanoma cells. The expression levels of miR‑145‑5p were decreased in melanoma tumor tissues and cell lines. TUG1 directly targeted miR‑145‑5p and downregulated miR‑145‑5p. Upregulation of TUG1 counteracted the promotion of the proliferative, migratory and invasive abilities of melanoma cells induced by the overexpression of miR‑145‑5p. SOX2 was a target of miR‑145‑5p and its expression was negatively regulated by miR‑145‑5p, while positively regulated by TUG1. TUG1 regulated SOX2 expression through sponging miR‑145‑5p. Silencing of TUG1 also inhibited melanoma tumorigenesis in mice. In conclusion, the TUG1/miR‑145‑5p/SOX2 axis regulated the migration and invasion of melanoma cells.

View Figures

View References

1	Ali Z, Yousaf N and Larkin J: Melanoma epidemiology, biology and prognosis. EJC Suppl. 11:81–91. 2013.PubMed/NCBI View Article : Google Scholar
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
3	Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.PubMed/NCBI View Article : Google Scholar
4	Abildgaard C and Guldberg P: Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med. 21:164–171. 2015.PubMed/NCBI View Article : Google Scholar
5	Fang Y and Fullwood MJ: Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 14:42–54. 2016.PubMed/NCBI View Article : Google Scholar
6	Li X, Wu Z, Fu X and Han W: lncRNAs: Insights into their function and mechanics in underlying disorders. Mutat Res Rev Mutat Res. 762:1–21. 2014.PubMed/NCBI View Article : Google Scholar
7	Yu X, Zheng H, Tse G, Zhang L and Wu WKK: CASC2: An emerging tumour-suppressing long noncoding RNA in human cancers and melanoma. Cell Prolif. 51(e12506)2018.PubMed/NCBI View Article : Google Scholar
8	Lu CW, Zhou DD, Xie T, Hao JL, Pant OP, Lu CB and Liu XF: HOXA11 antisense long noncoding RNA (HOXA11-AS): A promising lncRNA in human cancers. Cancer Med. 7:3792–3799. 2018.PubMed/NCBI View Article : Google Scholar
9	Liang L, Zhang Z, Qin X, Gao Y, Zhao P, Liu J and Zeng W: Long noncoding RNA ZFAS1 promotes tumorigenesis through regulation of miR-150-5p/RAB9A in melanoma. Melanoma Res. 29:569–581. 2019.PubMed/NCBI View Article : Google Scholar
10	Shi G, Li H, Gao F and Tan Q: lncRNA H19 predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration and epithelial-mesenchymal transition in melanoma cells. Onco Targets Ther. 11:3583–3595. 2018.PubMed/NCBI View Article : Google Scholar
11	Ghaforui-Fard S, Vafaee R and Taheri M: Taurine-upregulated gene 1: A functional long noncoding RNA in tumorigenesis. J Cell Physiol. 234:17100–17112. 2019.PubMed/NCBI View Article : Google Scholar
12	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014.PubMed/NCBI View Article : Google Scholar
13	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006.PubMed/NCBI View Article : Google Scholar
14	Jiang R, Zhao C, Gao B, Xu J, Song W and Shi P: Mixomics analysis of breast cancer: Long non-coding RNA linc01561 acts as ceRNA involved in the progression of breast cancer. Int J Biochem Cell Biol. 102:1–9. 2018.PubMed/NCBI View Article : Google Scholar
15	Zhang H, Jiang M, Liu Q, Han Z, Zhao Y and Ji S: miR-145-5p inhibits the proliferation and migration of bladder cancer cells by targeting TAGLN2. Oncol Lett. 16:6355–6360. 2018.PubMed/NCBI View Article : Google Scholar
16	Jin C, Wang A, Liu L, Wang G, Li G and Han Z: miR-145-5p inhibits tumor occurrence and metastasis through the NF-κB signaling pathway by targeting TLR4 in malignant melanoma. J Cell Biochem. 120:11115–11126. 2019.PubMed/NCBI View Article : Google Scholar
17	Grimm D, Bauer J, Wise P, Kruger M, Simonsen U, Wehland M, Infanger M and Corydon TJ: The role of SOX family members in solid tumours and metastasis. Semin Cancer Biol. 67:122–153. 2019.PubMed/NCBI View Article : Google Scholar
18	Andreucci E, Pietrobono S, Peppicelli S, Ruzzolini J, Bianchini F, Biagioni A, Stecca B and Calorini L: SOX2 as a novel contributor of oxidative metabolism in melanoma cells. Cell Commun Signal. 16(87)2018.PubMed/NCBI View Article : Google Scholar
19	Schaefer SM, Segalada C, Cheng PF, Bonalli M, Parfejevs V, Levesque MP, Dummer R, Nicolis SK and Sommer L: Sox2 is dispensable for primary melanoma and metastasis formation. Oncogene. 36:4516–4524. 2017.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Wang SH, Zhang WJ, Wu XC, Weng MZ, Zhang MD, Cai Q, Zhou D, Wang JD and Quan ZW: The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer. J Cell Mol Med. 20:2299–2308. 2016.PubMed/NCBI View Article : Google Scholar
22	Aldred AJ, Cha MC and Meckling-Gill KA: Determination of a humane endpoint in the L1210 model of murine leukemia. Contemp Top Lab Anim Sci. 41:24–27. 2002.PubMed/NCBI
23	Laga AC, Zhan Q, Weishaupt C, Ma J, Frank MH and Murphy GF: SOX2 and nestin expression in human melanoma: An immunohistochemical and experimental study. Exp Dermatol. 20:339–345. 2011.PubMed/NCBI View Article : Google Scholar
24	Singh S, Zafar A, Khan S and Naseem I: Towards therapeutic advances in melanoma management: An overview. Life Sci. 174:50–58. 2017.PubMed/NCBI View Article : Google Scholar
25	Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017.PubMed/NCBI View Article : Google Scholar
26	Yu X, Zheng H, Tse G, Chan MT and Wu WK: Long non-coding RNAs in melanoma. Cell Prolif. 51(e12457)2018.PubMed/NCBI View Article : Google Scholar
27	Richtig G, Ehall B, Richtig E, Aigelsreiter A, Gutschner T and Pichler M: Function and clinical implications of long non-coding RNAs in melanoma. Int J Mol Sci. 18(715)2017.PubMed/NCBI View Article : Google Scholar
28	Long J, Menggen Q, Wuren Q, Shi Q and Pi X: Long noncoding RNA taurine-upregulated gene1 (TUG1) promotes tumor growth and metastasis through TUG1/Mir-129-5p/astrocyte-elevated gene-1 (AEG-1) axis in malignant melanoma. Med Sci Monit. 24:1547–1559. 2018.PubMed/NCBI View Article : Google Scholar
29	Wang Y, Liu G, Ren L, Wang K and Liu A: Long non-coding RNA TUG1 recruits miR-29c-3p from its target gene RGS1 to promote proliferation and metastasis of melanoma cells. Int J Oncol. 54:1317–1326. 2019.PubMed/NCBI View Article : Google Scholar
30	Thomson DW and Dinger ME: Endogenous microRNA sponges: Evidence and controversy. Nat Rev Genet. 17:272–283. 2016.PubMed/NCBI View Article : Google Scholar
31	Zhuang S, Liu F and Wu P: Upregulation of long noncoding RNA TUG1 contributes to the development of laryngocarcinoma by targeting miR-145-5p/ROCK1 axis. J Cell Biochem. 120:13392–13402. 2019.PubMed/NCBI View Article : Google Scholar
32	Ren K, Li Z, Li Y, Zhang W and Han X: Long noncoding RNA taurine-upregulated gene 1 promotes cell proliferation and invasion in gastric cancer via negatively modulating miRNA-145-5p. Oncol Res. 25:789–798. 2017.PubMed/NCBI View Article : Google Scholar
33	Shi L, Tian C, Sun L, Cao F and Meng Z: The lncRNA TUG1/miR-145-5p/FGF10 regulates proliferation and migration in VSMCs of hypertension. Biochem Biophys Res Commun. 501:688–695. 2018.PubMed/NCBI View Article : Google Scholar
34	Zeng B, Ye H, Chen J, Cheng D, Cai C, Chen G, Chen X, Xin H, Tang C and Zeng J: LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis. Oncotarget. 8:113650–113661. 2017.PubMed/NCBI View Article : Google Scholar
35	Ozen M, Karatas OF, Gulluoglu S, Bayrak OF, Sevli S, Guzel E, Ekici ID, Caskurlu T, Solak M, Creighton CJ and Ittmann M: Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. Cancer invest. 33:251–258. 2015.PubMed/NCBI View Article : Google Scholar
36	Tang W, Zhang X, Tan W, Gao J, Pan L, Ye X, Chen L and Zheng W: miR-145-5p suppresses breast cancer progression by inhibiting SOX2. J Surg Res. 236:278–287. 2019.PubMed/NCBI View Article : Google Scholar
37	Zou G, Liu T, Guo L, Huang Y, Feng Y, Huang Q and Duan T: miR-145 modulates lncRNA-ROR and Sox2 expression to maintain human amniotic epithelial stem cell pluripotency and β islet-like cell differentiation efficiency. Gene. 591:48–57. 2016.PubMed/NCBI View Article : Google Scholar
38	Zeng H, Wang L, Wang J, Chen T, Li H, Zhang K, Chen J, Zhen S, Tuluhong D, Li J and Wang S: microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2. Arch Biochem Biophys. 651:52–60. 2018.PubMed/NCBI View Article : Google Scholar
39	Girouard SD, Laga AC, Mihm MC, Scolyer RA, Thompson JF, Zhan Q, Widlund HR, Lee CW and Murphy GF: SOX2 contributes to melanoma cell invasion. Lab Invest. 92:362–370. 2012.PubMed/NCBI View Article : Google Scholar
40	Fang W, Fan Y, Fa Z, Xu J, Yu H, Li P and Gu J: microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma. Oncotarget. 8:13253–13263. 2017.PubMed/NCBI View Article : Google Scholar